Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-10-02 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The document is a short announcement by Namyue Holdings notifying shareholders and the market of the date of a Board meeting to consider and approve the unaudited financial information for the nine months ended 30 September 2025. It does not contain any financial results itself, nor detailed report content, but solely the timing of a future report approval. This matches the definition of a Report Publication Announcement (RPA).
2025-10-02 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document is an announcement listing the company’s board of directors, including executive, non-executive, and independent non-executive directors, plus committee memberships effective from a specified date. This is a change or confirmation of board composition, which falls under Board/Management Information.
2025-09-30 English
CHANGE OF CHAIRMAN AND MANAGING DIRECTOR, EXECUTIVE DIRECTOR, CHAIRMAN AND MEMBER OF NOMINATION COMMITTEE AND CHANGE OF AUTHORISED REPRESENTATIVE
Board/Management Information Classification · 92% confidence The document is a formal announcement by the company’s Board of Directors regarding appointments and cessations of board and senior management positions (Executive Director, Chairman and Managing Director, Nomination Committee Chairman and member, and Authorised Representative). It details effective dates, biographies, and compliance with listing rules. This clearly falls under announcements of changes in the company's board or senior management.
2025-09-30 English
Interim Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT 2025' for Namyue Holdings Limited. It contains comprehensive financial statements, including the 'Condensed Consolidated Statement of Profit or Loss', 'Condensed Consolidated Statement of Financial Position', and 'Notes to Interim Condensed Consolidated Financial Statements', as well as a detailed 'Management Discussion and Analysis'. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-23 English
Interim Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is clearly identified as an 'INTERIM REPORT' for the year 2025 for TYK Medicines, Inc. It contains comprehensive financial statements (Statement of Profit or Loss, Financial Position, Cash Flows), management discussion and analysis (MDA), and business highlights. It is not an announcement of a report (RPA) because it contains the full content of the interim report itself. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes substantive financial data. H1 2025
2025-09-19 English
Notification Letter to Non-registered H Shareholders and Reply Form - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
Report Publication Announcement Classification · 84% confidence The document is a reminder letter to non-registered H shareholders regarding the electronic dissemination of corporate communications (annual report, interim report, meeting notices, circulars, proxy forms) and provides a reply form for requesting printed copies. It does not contain financial data or report content itself, but rather announces the distribution method and publication availability. This matches the “Report Publication Announcement” category (Code: RPA).
2025-09-17 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.